PF 03814735

Cat. No. 4821

PF 03814735 C23H25F3N6O2 [942487-16-3]

Price and Availability

For PF 03814735 pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: N-[2-[(1S,4R)-6-[[4-(Cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide

Biological Activity

ATP-competitive inhibitor of Aurora kinases A and B (IC50 values are 0.8 and 5 nM for recombinant Aurora B and Aurora A, respectively). Inhibits phosphorylation of Aurora B, histone H3 and Aurora A in cultured MDA-MB-231 cells (IC50 values are approximately 20, 50 and 150 nM respectively). Shown to block cytokinesis; inhibits cellular proliferation in several human tumor cell lines, including HCT-116, HL-60, A549 and H125, and in human xenograft mouse models. Orally available.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

Soluble to 100 mM in DMSO and to 20 mM in ethanol
>98 %
Store at -20°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

Hook et al (2012) An integrated genomic approach to identify predictive biomarkers of response to the Aurora kinase inhibitor PF-03814735. Mol.Cancer Ther. 11 710. PMID: 22222631.

Kollareddy et al (2012) Aurora kinase inhibitors: progress towards the clinic. Invest.New Drugs 30 2411. PMID: 22350019.

Jani et al (2010) PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol.Cancer Ther. 9 883. PMID: 20354118.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses PF 03814735 from Tocris? If so please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: PF 03814735, supplier, PF03814735, Pfizer, Aurora, kinase, A, B, inhibitors, inhibits, antiproliferative, Tocris Bioscience, Aurora Kinase Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

New Products in this Area


Potent and selective PFKFB3 inhibitor

STOCK2S 26016

Lysine deficient protein kinase (WNK) signaling inhibitor

rac-CCT 250863

Potent Nek2 inhibitor


Potent, selective cyclin-dependent kinase inhibitor


Potent PKCβ inhibitor

BMS 265246

Potent cdk1/2 inhibitor

Autocamtide-2-related inhibitory peptide, myristoylated

CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide

MP A08

Selective ATP competitive SphK1 and 2 inhibitor; cell permeable


Potent and selective dual Akt1 and 2 inhibitor

VX 680

High affinity and selective Aurora kinase inhibitor

Imatinib mesylate

Potent and selective v-Abl tyrosine kinase inhibitor; also inhibits PDGFR and c-kit

TGX 221

Potent and selective PI 3-kinase β inhibitor

PF 543 hydrochloride

Potent and selective SphK1 inhibitor

JX 06

Potent and selective pyruvate dehydrogenase kinase (PDK) 1/2/3 inhibitor

MRT 68601 hydrochloride

Potent TBK1 inhibitor

Sign-up for new product e-alerts
divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.